This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions.

The presentation slides which follow this notice and the oral presentation of which it forms part (together, the "Materials") are personal to the recipient and have been prepared and issued by or on behalf of the Company. For the purposes of the remainder of this notice, the term Materials shall include the presentation, the question-and-answer session that follows the presentation, hard or electronic copies of this document and any other materials distributed at, or in connection with, the presentation. The recipient agrees to return all Materials held by it in relation to the Placing upon the Company's request.

The information and opinions contained in this presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this presentation and any errors therein or omissions therefrom.

This presentation does not constitute or form any part of, and should not be construed as, an offer to sell, or an invitation or solicitation or recommendation to purchase, or subscribe for or underwrite or otherwise acquire any securities in the Company in any jurisdiction and does not constitute or form part of a prospectus. No part of this presentation should form the basis of, or be relied on in connection with, or act as any inducement to enter into, any contract or commitment or investment decision whatsoever. The Company’s nominated adviser, finnCap (“finnCap”) has not approved this document for the purposes of section 21 of the Financial Services and Markets Act 2000 (“FSMA”) and accordingly it is a communication made only to persons who (a) fall within one or more of the exemptions from section 21 of FSMA contained in articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) and persons who are otherwise permitted by law to receive it and (b) are an ‘eligible counterparty’ within the meaning of Article 24(2), (3) and (4) of Directive 2004/39/EC (“MiFID”) as implemented into national law of the relevant EEA state (together, the “Relevant Persons”). Any investment or investment activity to which this document relates is only available to the Relevant Persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to finnCap immediately.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under FSMA).

This presentation contains certain statements that are neither reported financial results nor other historical information. These statements include information with respect to the Company's financial condition, its results of operations and businesses, strategy, plans and objectives. Words such as “anticipates”, “expects”, “should”, “intends”, “plans”, “believes”, “outlook”, “seeks”, “estimates”, “targets”, “may”, “will”, “continue”, “project” and similar expressions, as well as statements in the future tense, identify forward-looking statements. These forward-looking statements are not guarantees of the Company’s future performance and are subject to assumptions, risks and uncertainties that could cause actual future results to differ materially from those expressed in or implied by such forward-looking statements. No statement in the Materials is intended to be nor may it be construed as a profit forecast. Many of these assumptions, risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely and include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Company’s and its subsidiaries’ (the “Group”) research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group’s products by customers.

For further details regarding these and other assumptions, risks and uncertainties that may affect the Group, please read the Directors’ Report section including the “Principal risks and uncertainties” in the most recent Annual Report & Accounts of the Company. In addition, new factors emerge from time to time and the Company cannot assess the potential impact of any such factor on its activities or the extent to which any factor, or combination of factors, may cause actual future results to differ materially from those contained in any forward-looking statement. Except as may be required by law or regulation, the Company undertakes no obligation to update any of its forward-looking statements, which speak only as of the date of this document.
Strengthening a leading position in emerging $ multi-billion liquid biopsy market

**ANGLE’s Parsortix™ system is a simple blood test for personalised cancer care, which harvests viable intact cancer cells (CTCs) for analysis**
- unique patented microfluidic approach, strongly differentiated from competition
- platform has been shown to work with 21 different cancer types
- also works for cancer lymph node analysis and for harvesting fetal cells
- CTCs have greater clinical utility than ctDNA (fragments of dead cells) as viable intact cancer cells provide the Complete Picture including DNA, RNA, and protein analysis as well as the potential to culture the cells outside the patient

**ANGLE’s product-based solution provides a highly leveraged business model which is scaleable**
- products are low cost but high value with instruments and consumables giving high gross margins >70%
- c. 200 instruments in active use with >60,000 blood separations
- Parsortix widely used by leading researchers, generating new applications for the platform through breakthrough research
- third party published evidence of performance is growing rapidly with 16 peer-reviewed publications and numerous posters published by 19 cancer centres
- outsourced manufacturing suppliers able to scale rapidly without Company capex

**On track to be the first company with FDA clearance for harvesting cancer cells from blood for analysis**
- enrolment of 400 subjects for FDA clinical study is 92% complete
- clinical and analytical studies to support FDA clearance due to complete in Q1 CY19
- prospect of FDA clearance in metastatic breast cancer in CY 2019
- major validation as only the third FDA clearance in liquid biopsy

**Large scale clinical studies in ovarian cancer significantly out-performed existing standard of care**
- 400 patient studies serve as the exemplar for other applications
- Parsortix HyCEAD Ziplex combination showed 95.1% accuracy (AUC-ROC) in detecting ovarian cancer in women having surgery for an abnormal pelvic mass
- abnormal pelvic mass conditions affect 5-10% of all women
- estimated market size is $1 billion p.a.
- ovarian assay has been further optimised and a new clinical verification study is due to start in early 2019

**Commercial partnership strategy to leverage sales and distribution channels**
- combines ANGLE’s cancer cell harvesting capability with existing large players’ downstream analysis platforms
- partnership with Abbott for HER-2 testing in breast cancer
- partnership with QIAGEN for AR-V7 testing in prostate cancer
- European research project with Philips combining liquid biopsy with imaging
- progressing other partnerships in cancer and non-invasive prenatal diagnosis

**ANGLE’s HyCEAD Ziplex downstream analysis system offers sample-to-answer growth potential**
- optimised to provide high sensitivity for multi-gene panel analysis
- first use ovarian but also offers access to new markets
Continued strong progress during half year

- FDA analytical and clinical studies nearing completion
- HyCEAD Ziplex platform further developed delivering outstanding sensitivity for multi gene panel downstream analysis
- Ovarian cancer test combining Parsortix and HyCEAD Ziplex systems successfully developed with clinical verification study pending ethics approval
- Leveraged partnership strategy delivers key benefits
  - ANGLE and QIAGEN co-marketing of combined product offering
  - CTC clusters research breakthrough
  - lymph node analysis
  - pilot study in fetal
Breast cancer FDA clearance progress

Analytical studies progressing well
- precision and reproducibility
- accuracy and linearity
- limits of quantification and detection
- interferents and carryover

FDA clinical study in progress
- 200 metastatic breast cancer patients and 200 age appropriate healthy volunteers
- enrolment already at 369 subjects 92% complete
- MD Anderson leading primary endpoint analysis to confirm CTCs harvested for analysis
- Secondary endpoints qPCR, FISH (Abbott), RNA-Seq

Four 4 leading US cancer centres enrolling
- University of Texas MD Anderson Cancer Center
- University of Southern California Norris Cancer Center
- University of Rochester Wilmot Cancer Center
- Robert H Lurie Cancer Center Northwestern University

Studies expected to complete Q1 CY19

Analysis of results and detailed drafting of submission to allow FDA filing

Prospect of FDA clearance in CY 2019
HyCEAD Ziplex® high performance multiplex downstream analysis solution

- **Downstream analysis platform HyCEAD Ziplex**
  - acquired November 2017 providing multiplex cancer gene expression
  - Analysis of >100 genes in a single reaction
  - similar to targeted NGS at price of PCR

- **Completed extensive improvements to the platform**
  - sensitivity sufficient to detect a single cancer cell harvested by Parsortix
  - process controls incorporated to track assay and instrument performance
  - patient blood stability demonstrated for up to 96 hours

- **Potential to open up a completely new set of markets** as it can be deployed with many other sample types not just CTCs
Ovarian cancer pelvic mass triage test

- 400 patient clinical studies demonstrate potential to **significantly out-perform current clinical care** in discriminating malignant from benign with HyCEAD Ziplex study demonstrating **ROC-AUC 95.1%**

- **Extensive optimisation of the ovarian assay following detailed user requirement survey.** Entire “sample-to-answer” process has been analytically validated and is now ready to evaluate in the clinical setting.

- Optimisation now offers the **ability to detect and analyse a single cancer cell** in a Parsortix harvest from 10ml of patient blood.

- A **clinical verification study has been designed and submitted** to the University of Rochester Wilmott Cancer Center for ethics IRB approval.

- Ovarian **clinical verification study is expected to commence in Q1 CY2019** with completion expected 12 months later.

- **ANGLE intends to engage with large scale clinical laboratories and/or women’s health companies** to secure a partner for clinical deployment utilising their sales and distribution channels to scale deployment.
Leveraged partnership strategy

- **Abbott: breast cancer HER-2**
  - process for using Abbott HER-2 FISH test with Parsortix harvested CTCs developed and deployed in FDA clinical study
  - discussions with Abbott being progressed regarding sales and distribution of the test

- **QIAGEN: prostate cancer AR-V7**
  - joint poster published at international cancer conference
  - joint marketing flyer prepared
  - further work on combining ANGLE cancer cell harvesting with QIAGEN downstream analysis

- **Philips: combination of liquid biopsy with imaging**
  - European research funded collaboration over 4 years

- **Other: multiple other partnerships under consideration**
  - fetal and HyCEAD Ziplex as well as other Parsortix cancer collaborations
Research use drives growing body of evidence and delivers breakthrough research

- **Growing user base** (in-house, KOLs, customers and evaluations)
  - over 60,000 blood separations performed with c. 200 Parsortix instruments in active use
  - 16 peer-reviewed publications and numerous posters from 19 cancer centres

- **Basel CTC cluster study identifies therapies to reduce metastasis**
  - breakthrough research over three years by leading customer reducing metastasis in mouse model by 80x
  - prospect for routine repeat use of Parsortix as a companion diagnostic
  - Basel planning breast cancer clinical study in 2019

- **Glioblastoma**
  - ability to harvest CTCs and CTC clusters from blood opens potential for non-invasive biopsy

- **Lymph node analysis in melanoma**
  - improved process for detecting cancer cells in lymph node with added benefit of facilitating molecular analysis

- **Fetal cells in pregnant women blood**
  - pilot study demonstrates ability to harvest fetal cells from the blood of pregnant women
  - potential to provide much wider information on fetal health than current NIPT which is based on cell-free fetal DNA
  - seeking partner for commercialisation
**Financial Highlights for the six months ended 31 October 2018**

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Statement of Comprehensive Income</strong></td>
<td>£'000</td>
<td>£'000</td>
</tr>
<tr>
<td><strong>Revenue and grant income</strong></td>
<td>370</td>
<td>188</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>(69)</td>
<td>(54)</td>
</tr>
<tr>
<td><strong>Gross profit and grant income</strong></td>
<td>301</td>
<td>134</td>
</tr>
<tr>
<td><strong>Operating costs</strong></td>
<td>(5,340)</td>
<td>(4,245)</td>
</tr>
<tr>
<td><strong>Other income</strong></td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td><strong>Loss before tax from continuing operations</strong></td>
<td>(5,029)</td>
<td>(4,110)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>31Oct18</th>
<th>30Apr18</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Statement of Financial Position</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and other receivables and R&amp;D tax credit</td>
<td>2,591</td>
<td>2,975</td>
</tr>
<tr>
<td>Inventories</td>
<td>880</td>
<td>599</td>
</tr>
<tr>
<td>Cash</td>
<td>14,874</td>
<td>7,645</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>1,403</td>
<td>1,475</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>5,797</td>
<td>5,588</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>25,545</td>
<td>18,282</td>
</tr>
</tbody>
</table>

**Comments**

- Revenue and grant income up 97%
  - c. 200 Parsortix instruments in active use
  - >60,000 blood separations have already been performed on the Parsortix system
- >70% gross margin
- Planned expenditure on clinical studies
- Cash position strengthened with £12m fundraise (net)
- Strengthening a leading position in $ multi-billion emerging market
Team strengthened with new appointments

Board appointment: Non-executive director

Dr Jan Groen
CEO MDxHealth, a genomic diagnostics company in prostate and bladder cancers. Previously President Agenda, co-founder of ViroClinics and DxOrange. Management positions at Focus Diagnostics, a subsidiary of Quest Diagnostics, and Akzo-Nobel. PhD Medical Microbiology, BSc in Clinical Laboratory Studies

Scientific Adviser appointments

Dr Joseph Khoury, Professor of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center in Houston. Director of the MD Anderson Institutional Immunohistochemistry Laboratory. Member of the College of American Pathologists.

Mr Greg L Shaw, Consultant Urological Surgeon at University College Hospital in London. Chief investigator for NIHR portfolio studies investigating 1) the effects on refinements to robotic surgery and 2) the use of drugs to prevent progression in men on active surveillance for prostate cancer respectively. Expert in robotic surgery with a high case volume
Key next steps

- Clinical and analytical studies to support first ever FDA clearance to harvest cancer cells from patient blood for subsequent analysis expected to complete in Q1 CY19
- Prospect of FDA clearance in CY 2019
- Ovarian cancer clinical verification study due to start in Q1 CY19 utilising sample-to-answer system (Parsortix-HyCEAD-Ziplex) with completion expected 12 months later
- Progression of existing partnerships and establishment of new partnerships with medtech (downstream analysis), pharma (companion diagnostics), CRO (drug trials), clinical laboratories (LDT)
Strengthening a leading position in emerging $ multi-billion liquid biopsy market

**ANGLE’s Parsortix™ system is a simple blood test for personalised cancer care, which harvests viable intact cancer cells (CTCs) for analysis**
- unique patented microfluidic approach, strongly differentiated from competition
- platform has been shown to work with **21 different cancer types**
- also works for cancer lymph node analysis and for harvesting fetal cells
- CTCs have greater clinical utility than ctDNA (fragments of dead cells) as viable intact cancer cells provide the **Complete Picture** including DNA, RNA, and protein analysis as well as the potential to culture the cells outside the patient

**ANGLE’s product-based solution provides a highly leveraged business model which is scaleable**
- products are low cost but high value with instruments and consumables giving high gross margins >70%
- **c. 200 instruments in active use with >60,000 blood separations**
- Parsortix widely used by leading researchers, generating new applications for the platform through breakthrough research
- third party published evidence of performance is growing rapidly with **16 peer-reviewed publications** and numerous posters published by **19 cancer centres**
- outsourced manufacturing suppliers able to scale rapidly without Company capex

**On track to be the first company with FDA clearance for harvesting cancer cells from blood for analysis**
- enrolment of 400 subjects for FDA clinical study is **92% complete**
- clinical and analytical studies to support FDA clearance due to complete in Q1 CY19
- prospect of FDA clearance in metastatic breast cancer in CY 2019
- major validation as only the third FDA clearance in liquid biopsy

**Large scale clinical studies in ovarian cancer significantly out-performed existing standard of care**
- 400 patient studies serve as the exemplar for other applications
- Parsortix HyCEAD Ziplex combination showed **95.1% accuracy (AUC-ROC)** in detecting ovarian cancer in women having surgery for an abnormal pelvic mass
- estimated market size is $1 billion p.a.
- ovarian assay has been further optimised and a new clinical verification study is due to start in early 2019

**Commercial partnership strategy to leverage sales and distribution channels**
- combines ANGLE’s cancer cell harvesting capability with existing large players’ downstream analysis platforms
- partnership with **Abbott** for HER-2 testing in breast cancer
- partnership with **QIAGEN** for AR-V7 testing in prostate cancer
- European research project with **Philips** combining liquid biopsy with imaging
- progressing other partnerships in cancer and non-invasive prenatal diagnosis

**ANGLE’s HyCEAD Ziplex downstream analysis system offers sample-to-answer growth potential**
- optimised to provide high sensitivity for multi-gene panel analysis
- first use ovarian but also offers access to new markets